Advertisement
IONS or JNJ or MRK
Which Stock Would AI Choose? Ionis Pharmaceuticals (IONS) vs. Johnson & Johnson (JNJ) vs. Merck & Co (MRK) Stock Comparison
Key Takeaways
- IONS exhibits high volatility with strong one-year gains over 119%, driven by positive clinical data for olezarsen, though recent months show pullbacks.
- JNJ leads in stability and YTD performance at 17.4%, bolstered by oncology innovations and diversified revenue streams.
- MRK delivers solid YTD returns around 10%, supported by Keytruda sales and pipeline advancements, but faces patent concerns.
- JNJ and MRK offer dividends and lower betas, appealing for defensive positioning amid market fluctuations.
- Biotech-focused IONS trades at a growth premium, contrasting the value-oriented valuations of JNJ (P/E 21.9) and MRK (P/E 15.9).
- Relative performance highlights JNJ's outperformance in recent market activity, balancing growth and resilience.
Introduction
This stock comparison evaluates IONS, JNJ, and MRK in the healthcare sector, spanning biotech innovation and established pharmaceuticals. Investors seeking growth via RNA-targeted therapies may eye IONS, while those prioritizing stability and dividends favor JNJ or MRK. Traders analyzing relative performance benefit from insights into recent momentum, pipeline catalysts, and sector exposure. With healthcare resilience amid economic shifts, this analysis aids decisions on stock positioning, relative strength, and market dynamics.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS), a commercial-stage biotech, pioneers RNA-targeted medicines for neurology, cardiometabolic, and rare diseases. Marketed products include TRYNGOLZA for triglycerides, WAINUA for amyloidosis, and SPINRAZA royalties. In recent market activity, shares traded around $72, within a 52-week range of $24-$87, reflecting volatility with one-year gains exceeding 119% but YTD down 8.6% and monthly declines near 11%. Sentiment shifted positively on FDA priority review for olezarsen in severe hypertriglyceridemia (sHTG), boosting peak sales estimates over $2 billion, alongside DAWNZERA data in hereditary angioedema. Q4 2025 revenue beat estimates at $203 million despite EPS loss, fueling pipeline optimism but exposing biotech risks like trial outcomes.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ), a diversified healthcare giant, operates in Innovative Medicine (oncology, immunology) and MedTech (surgery, vision). Recent weeks saw shares near $241, in a 52-week range of $142-$252, with YTD gains of 17.4% and one-year returns over 52%. Performance reflects oncology momentum, including bladder cancer therapies and TECVAYLI expansion in multiple myeloma, plus FDA approval for TECNIS PureSee IOL. Q4 2025 sales hit $24.6 billion, beating estimates, with 2026 guidance at $100-101 billion. Analyst upgrades, like Citi's $274 target, underscore stability (beta 0.35), though talc litigation lingers as a risk factor influencing measured sentiment.
MRK Overview and Recent Performance
Merck & Co. (MRK), a research-intensive biopharma, leads with Keytruda in oncology, vaccines like Gardasil, and animal health. Shares hovered around $116, in a 52-week range of $73-$125, posting YTD gains near 10% and one-year up 22%. Recent activity featured positive WELIREG kidney cancer data and Keytruda trial results, with analysts raising targets to $150 amid oncology and fertility potential. Q4 2025 sales reached $16.4 billion, full-year $65 billion, though Gardasil slumps prompted layoffs. Keytruda patent expiry looms, tempering sentiment despite pipeline depth and moderate beta.
Trending AI Robots
Tickeron’s Trending AI Robots page curates top AI trading bots from hundreds available, each trading thousands of tickers across diverse strategies like trend following, volatility plays, and hedging. Selected for current market conditions, these 25 bots from 351 total showcase annualized returns up to +202%, win rates to 94.92%, and profit factors over 25. Examples include a biotech bot (BIB) at +23% return/94.92% win rate and multi-sector leaders like semiconductors/oil at +129%/61.65% win rate. With timeframes from 1-62 days and drawdowns managed via stop-losses, they suit various risk profiles. Explore these high performers adapting to volatility for potential edge in stock trading.
Head-to-Head Comparison
IONS focuses on high-growth biotech via RNA therapies, contrasting JNJ and MRK's diversified pharma models with broad oncology/vaccine exposure. Growth drivers differ: IONS pipeline catalysts like olezarsen offer upside but trial risks; JNJ leverages MedTech stability; MRK Keytruda dominance faces 2028 expiry. Recent momentum favors JNJ (YTD 17%), over MRK (10%) and IONS (-9%). Risks include IONS volatility (beta 0.36), JNJ litigation, MRK generics. Valuation sensitivity shows MRK cheapest (P/E 16), JNJ balanced (22), IONS premium growth. Sentiment tilts to JNJ's resilience in healthcare rotations.
Tickeron AI Verdict
Tickeron’s AI currently favors JNJ for its trend consistency, YTD leadership, diversified catalysts, and defensive beta amid volatility. While IONS shows pipeline momentum and MRK value appeal, JNJ's relative positioning and stability suggest higher probability of outperformance in the near term, based on observable revenue beats and analyst support.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IONS’s FA Score shows that 0 FA rating(s) are green whileJNJ’s FA Score has 3 green FA rating(s), and MRK’s FA Score reflects 3 green FA rating(s).
- IONS’s FA Score: 0 green, 5 red.
- JNJ’s FA Score: 3 green, 2 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IONS’s TA Score shows that 4 TA indicator(s) are bullish while JNJ’s TA Score has 3 bullish TA indicator(s), and MRK’s TA Score reflects 4 bullish TA indicator(s).
- IONS’s TA Score: 4 bullish, 4 bearish.
- JNJ’s TA Score: 3 bullish, 6 bearish.
- MRK’s TA Score: 4 bullish, 4 bearish.
Price Growth
IONS (@Biotechnology) experienced а +0.72% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -1.79% , and MRK (@Pharmaceuticals: Major) price fluctuated -1.94% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.21%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was +7.89%.
Reported Earning Dates
IONS is expected to report earnings on Apr 29, 2026.
JNJ is expected to report earnings on Jul 22, 2026.
MRK is expected to report earnings on Apr 30, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (+1.21% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| IONS | JNJ | MRK | |
| Capitalization | 12.5B | 564B | 294B |
| EBITDA | -273.12M | 41.1B | 28.3B |
| Gain YTD | -4.298 | 13.759 | 13.958 |
| P/E Ratio | N/A | 21.23 | 16.36 |
| Revenue | 944M | 94.2B | 65B |
| Total Cash | 2.68B | 20.1B | N/A |
| Total Debt | 2.07B | 47.9B | 49.3B |
IONS | JNJ | MRK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 8 | 57 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 100 Overvalued | 26 Undervalued | 21 Undervalued | |
PROFIT vs RISK RATING 1..100 | 62 | 11 | 48 | |
SMR RATING 1..100 | 98 | 27 | 25 | |
PRICE GROWTH RATING 1..100 | 41 | 45 | 44 | |
P/E GROWTH RATING 1..100 | 74 | 41 | 28 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRK's Valuation (21) in the Pharmaceuticals Major industry is in the same range as JNJ (26) in the Pharmaceuticals Major industry, and is significantly better than the same rating for IONS (100) in the Biotechnology industry. This means that MRK's stock grew similarly to JNJ’s and significantly faster than IONS’s over the last 12 months.
JNJ's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (48) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for IONS (62) in the Biotechnology industry. This means that JNJ's stock grew somewhat faster than MRK’s and somewhat faster than IONS’s over the last 12 months.
MRK's SMR Rating (25) in the Pharmaceuticals Major industry is in the same range as JNJ (27) in the Pharmaceuticals Major industry, and is significantly better than the same rating for IONS (98) in the Biotechnology industry. This means that MRK's stock grew similarly to JNJ’s and significantly faster than IONS’s over the last 12 months.
IONS's Price Growth Rating (41) in the Biotechnology industry is in the same range as MRK (44) in the Pharmaceuticals Major industry, and is in the same range as JNJ (45) in the Pharmaceuticals Major industry. This means that IONS's stock grew similarly to MRK’s and similarly to JNJ’s over the last 12 months.
MRK's P/E Growth Rating (28) in the Pharmaceuticals Major industry is in the same range as JNJ (41) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for IONS (74) in the Biotechnology industry. This means that MRK's stock grew similarly to JNJ’s and somewhat faster than IONS’s over the last 12 months.
| IONS | JNJ | MRK | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 75% | 2 days ago 42% | 2 days ago 62% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 52% | 2 days ago 47% |
| MACD ODDS (%) | 2 days ago 73% | 2 days ago 32% | 2 days ago 59% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 40% | 2 days ago 48% |
| TrendMonth ODDS (%) | 2 days ago 74% | 2 days ago 42% | 2 days ago 52% |
| Advances ODDS (%) | 4 days ago 66% | 10 days ago 44% | 17 days ago 52% |
| Declines ODDS (%) | 6 days ago 65% | 2 days ago 41% | 3 days ago 50% |
| BollingerBands ODDS (%) | 2 days ago 67% | 2 days ago 48% | 2 days ago 69% |
| Aroon ODDS (%) | 2 days ago 74% | 2 days ago 38% | 2 days ago 54% |
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with PFE. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To MRK | 1D Price Change % | ||
|---|---|---|---|---|
| MRK | 100% | +3.13% | ||
| PFE - MRK | 63% Loosely correlated | +1.25% | ||
| BMY - MRK | 62% Loosely correlated | +2.05% | ||
| BIIB - MRK | 55% Loosely correlated | +0.76% | ||
| GSK - MRK | 54% Loosely correlated | +2.14% | ||
| AMGN - MRK | 54% Loosely correlated | +1.69% | ||
More | ||||